DSG1 and pemphigus: Finally, another study on biomarkers predictive of relapse in rituximab‐treated pemphigus patients showed that the relapse was associated with positivity for either anti‐Dsg1 or anti‐Dsg3 antibodies in serial ELISA tests after rituximab treatment.21